Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lymphoma Study Association
With
Bayer
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged from 18 to 65 years.
Patient with pathologically proven, high grade B-cell Lymphoma CD 20 positive (WHO classification) :
Diffuse large B cell lymphoma.
Adverse prognostic factors IPI\>1
In Complete Remission, or partial response to first line treatment.
Previously treated with chemotherapy regimen containing rituximab: R CHOP or R ACVBP
Chemo-sensitive disease
PET Scan prior transplant
Eligible for autologous stem cell transplantation
With a minimum life expectancy of 3 months.
Negative HIV, HBV and HCV serologies (in the last 4 weeks except after vaccination).
Having previously signed a written informed consent.
You may not be if
Histological transformation in diffuse large B cell lymphoma, any type of low grade lymphoma
More than one line of treatment. Prior transplantation. Prior exposure to Zevalin
Central nervous system or meningeal involvement by lymphoma.
Contraindication to any drug contained in the chemotherapy regimen.
Any serious active disease or co-morbid medical condition (according to the investigator's decision and information provided in the IDB).
Poor renal function (creatinin level up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
Poor hepatic function (total bilirubin level up to 30 micro mol/l, transaminases up to 2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
Poor bone marrow reserve as defined by neutrophils less than 1.5 G/l or platelets less than 100 G/l
Large bone marrow irradiation more than 40percent.
Bone marrow infiltration
Lack of sufficient autologous hematopoietic stem cells for transplantation.
Prior treatment with murine antibodies
Known hypersensibility to murine antibodies or proteins
Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
Adult patient unable to give informed consent because of intellectual impairment.
Pregnant or lactating women.
Clareo Health | Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
